Vapotherm does not practice medicine or provide medical services or advice. These guidelines are based on an assessment of physician interviews, and physiological modeling. Providers should refer to the full indications for use and operating instructions of any products referenced before use.
Winter is coming. Winter, as in, Respiratory Syncytial Virus (RSV) season. Last year’s RSV season hit the US earlier and harder with a record-breaking mix of strep infections, flu, RSV, and enteroviruses to compete with COVID. 
According to the CDC, during the 2022 season, early epidemic onsets (April-June) were observed in Florida and some regions (New England, Georgia, Texas), however, RSV leveled off before increasing again in September. Regions more north and west (New York, Colorado, California, and Washington) experienced RSV season peak in October and November (see figure 1).
FIGURE 1. Percentage* of polymerase chain reaction test results positive for respiratory syncytial virus, by epidemiologic week — National Respiratory and Enteric Virus Surveillance System, United States, July 2017–February 2023
*Three-week centered moving averages of percentage of RSV-positive PCR test results nationally.
The threshold for a seasonal epidemic was set at 3% RSV-positive PCR test results (not based on a moving average).
No matter where you are or when you might experience this year’s RSV smacking, you’re not alone.
Below is clinical evidence to support use of high velocity therapy if you are not already using it on these types of patients and tools for those that already are:
Here’s why you should consider High Velocity Therapy:
- Learn how high velocity therapy is a front-line tool for patients admitted to the ICU with severe bronchiolitis (a randomized controlled study). The study’s outcomes showed no failures in the high velocity therapy group and seven treatment failures in the oxygen diffuser group. Other results included a shorter length of stay (LOS) in the PICU and hospital.
- Patients of Vapotherm High Velocity Therapy showed similar outcomes to CPAP for infants with Moderate to Severe Bronchiolitis. (a pilot study)
- Lastly, this study suggests that High Flow Nasal Cannulas (HFNC) are well tolerated for orally feeding children with bronchiolitis. You can learn more here.
Here’s some resources for you to share with your team:
- You can learn more and receive 1 CRCE under the Neonatal-Pediatric category by completing this course by Dr. Alexandre Rotta on High Velocity Therapy in Critical Bronchiolitis.
- Download a free pediatric pocket guide to learn more on patient assessment, starting flow rates, and cannula sizing.
You’re not alone.
Most importantly, we want you to know that you’re not alone. Our goal is to keep kids off the vent and to help you get through this RSV season. Vapotherm is here for any High Velocity Therapy educational or training needs. Complete this form to be connected to your account manager.
Learn More About Vapotherm
 Viruses and other bugs could make a summer comeback. https://www.nbcnews.com/health/health-news/summer-illnesses-watch-2023-covid-hmpv-lyme-disease-rcna87350
 Seasonality of Respiratory Syncytial Virus — United States, 2017–2023. https://www.cdc.gov/mmwr/volumes/72/wr/mm7214a1.htm